Sickle cell disease has been shown to demonstrate extensive variability in disease severity among and between individuals,the variability highlighted by differing genetic haplotypes.Despite the abundance of reports of...Sickle cell disease has been shown to demonstrate extensive variability in disease severity among and between individuals,the variability highlighted by differing genetic haplotypes.Despite the abundance of reports of functional significance due to polymorphisms of endothelial nitric oxide synthase(eNOS)and endothelin-1(ET-1)genes,the role of these polymorphisms in mediating sickle cell disease pathophysiology among African Americans is presently unclear.To deconvolute their potential significance among African Americans with sickle cell disease,we examined the genetic diversity and haplotype frequency of eNOS and ET-1 polymorphisms in disease(n Z 331)and control(n Z 379)groups,with a polymerase echain reaction restriction fragment length polymorphism assay.We report that genotypic and allelic frequencies of eNOS variants are not significantly different between groups.eNOS homozygote mutants,which had been shown to have clinical significance elsewhere,showed no statistical significance in our study.On the other hand,and contrary to previous report among Africans with sickle cell disease,the endothelin-1 homozygous mutant variant showed significant difference in genotypic(p Z 2.84E-12)and allelic frequencies(p Z 2.20E-16)between groups.The most common haplotype is the combination of T786C homozygote wildtype variant with homozygote mutant variants of G5665T(ET-1)and Glu298Asp(eNOS).These results show that endothelin-1(rs5370)polymorphism,rather than endothelial nitric oxide synthase polymorphism might play a significant role in disease severity or individual clinical outcomes among African Americans with sickle cell disease.This would have profound implications for designing and/or advancing personalized care for sickle cell patients and relieving disease complications.展开更多
基金We are grateful to Betty Pace and Joann Moulds who graciously provided us with the genomic DNA samples.We acknowledge the assistance of Yi Li,Shanxi University,China with data analysis.This project was supported by a Research Laboratory Support and Faculty Development Award,College of Health Sciences and Technology,Rochester Institute of Technology(BNT).An ABRCMS Travel Award(KGN)to present this work at the Annual Biomedical Research Conference for Minority Students,Seattle WA November 12e15,2015 is acknowledged.
文摘Sickle cell disease has been shown to demonstrate extensive variability in disease severity among and between individuals,the variability highlighted by differing genetic haplotypes.Despite the abundance of reports of functional significance due to polymorphisms of endothelial nitric oxide synthase(eNOS)and endothelin-1(ET-1)genes,the role of these polymorphisms in mediating sickle cell disease pathophysiology among African Americans is presently unclear.To deconvolute their potential significance among African Americans with sickle cell disease,we examined the genetic diversity and haplotype frequency of eNOS and ET-1 polymorphisms in disease(n Z 331)and control(n Z 379)groups,with a polymerase echain reaction restriction fragment length polymorphism assay.We report that genotypic and allelic frequencies of eNOS variants are not significantly different between groups.eNOS homozygote mutants,which had been shown to have clinical significance elsewhere,showed no statistical significance in our study.On the other hand,and contrary to previous report among Africans with sickle cell disease,the endothelin-1 homozygous mutant variant showed significant difference in genotypic(p Z 2.84E-12)and allelic frequencies(p Z 2.20E-16)between groups.The most common haplotype is the combination of T786C homozygote wildtype variant with homozygote mutant variants of G5665T(ET-1)and Glu298Asp(eNOS).These results show that endothelin-1(rs5370)polymorphism,rather than endothelial nitric oxide synthase polymorphism might play a significant role in disease severity or individual clinical outcomes among African Americans with sickle cell disease.This would have profound implications for designing and/or advancing personalized care for sickle cell patients and relieving disease complications.
